FibroBiologics has initiated a Phase 1/2 trial of CYWC628, an allogeneic fibroblast-spheroid cell therapy applied topically to diabetic foot ulcers. The 120-patient study evaluates whether this regenerative approach accelerates wound healing beyond standard care alone, with interim analysis planned at six weeks.
Key Points
- Fibroblast-spheroid cell therapy topically applied to diabetic foot ulcers
- Phase 1/2 trial enrolling 120 patients across multiple Australian sites
- Interim safety and efficacy assessment at six weeks of treatment
Longevity Analysis
Diabetic foot ulcers represent a critical failure point in circulation and tissue regeneration—complications that accelerate aging and functional decline. A cell-based regenerative approach addresses root dysfunction rather than managing symptoms, potentially restoring the body's capacity to repair damaged tissue. Success here would establish a template for using allogeneic cellular therapies to restore function in degenerative conditions driven by impaired wound healing and inflammatory burden.
Original published by LT Wire.